TuHURA Biosciences, Inc. (HURA) Stock

Healthcare · Biotechnology · Member of Other US Stocks

TuHURA Biosciences, Inc. (HURA) closed at USD 1.76 on 2026-10-14, a change of -28.5 % over the past year, with a market capitalization of USD 116.62M.

TuHURA Biosciences, Inc. recent closing prices

DateClose (USD)
2026-10-141.76
2026-10-131.81
2026-10-121.90
2026-10-091.96
2026-10-081.93
2026-10-071.98
2026-10-061.95

The most recent trading day is not shown. For full charts and indicators use the analysis page.

TuHURA Biosciences, Inc. key figures

Previous close
USD 1.76 (2026-10-14)
1-year change
-28.5 %
Market cap
USD 116.62M
Enterprise value
USD 125.08M
P/E ratio (trailing)
-3.45
P/E ratio (forward)
-3.03
EPS (trailing)
-0.53
EPS (forward)
-0.61
PEG ratio
n/a
Price to book
6.40
Revenue growth
n/a
Earnings growth
n/a
Dividend per share (trailing)
0.00
Short ratio
29.41
Employees
22
Analyst consensus (third-party)
none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About TuHURA Biosciences, Inc.

TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. It is also preparing to initiate a single randomized placebo-controlled which is in Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda; and Delta receptor technology to develop tumor microenvironment modulators in the form of first-in-class bi-functional and bi-specific antibody-drug conjugates targeting Myeloid Derived Suppressor Cells. In addition, the company is also developing Immune Fx; IFx-3.0, an mRNA innate immune agonist candidate for intravenous or autologous whole cell administration for blood-related cancers. The company was formerly known as Morphogenesis, Inc. and changed its name to TuHURA Biosciences, Inc. in December 2023. The company was founded in 1995 and is based in Tampa, Florida. TuHURA Biosciences, Inc. operates as a subsidiary of CohBar, Inc.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for TuHURA Biosciences, Inc. and compare it with other stocks.

Analyze HURAAll Other US Stocks stocks

Stock-scoring.com provides this page for information only. It is not investment advice or a recommendation to buy or sell TuHURA Biosciences, Inc. shares.